FOB Holdings Overseas News
Technology · US Patent

Binotec’s HYDROCUMIN Receives US Patent Allowance — a Nano Ingredient That Overcomes Curcumin’s Absorption Limits

USPTO issues Notice of Allowance for a surface-modified curcumin nanoparticle complex
At one-fifth the dose, peak blood level 11.6 times higher than standard curcumin — about 60 times on an equal-dose basis
After the Absosome delivery platform, the ingredient built on it moves toward US patent protection

[Binotec Announcement] | October 18, 2026 | Published in eight languages

HYDROCUMIN™, an oral curcumin ingredient developed by Korean bio-materials company Binotec, has received a US patent allowance.

Binotec said the US Patent and Trademark Office (USPTO) issued a Notice of Allowance on September 18, 2026 for its application titled “Curcumin nanoparticle complex having modified particle surface and method for preparing same” (Application No. 18/459,927). A Notice of Allowance means the examiner has found that the application meets the requirements for a patent; the patent is formally granted after follow-up steps such as payment of the issue fee.

HYDROCUMIN stick packs and the structure of its nano carrier. Curcumin is encapsulated in a carrier whose particle surface is then modified to form a complex. (Photo: Binotec)
HYDROCUMIN stick packs and the structure of its nano carrier. Curcumin is encapsulated in a carrier whose particle surface is then modified to form a complex. (Photo: Binotec)

Curcumin’s long-standing problem: absorption

Curcumin, the main bioactive compound in turmeric, is widely used in health functional foods and food ingredients. But it dissolves poorly in water and is poorly absorbed, so raising the amount that actually reaches the bloodstream has long been a major technical challenge.

Turmeric and curcumin are also major herbal ingredients in the United States. According to HerbalGram, the market report published by the American Botanical Council (ABC), turmeric and curcumin have ranked as the top-selling herbal ingredient in the US natural products channel since 2013, with sales of US$37.1 million in 2024.

Encapsulated in Absosome, with a modified particle surface

To overcome this limitation, Binotec developed HYDROCUMIN using its own oral delivery technology, Absosome™. Curcumin is encapsulated in the carrier, and the surface of the nanoparticle is then modified to form a complex.

HYDROCUMIN and the USPTO Notice of Allowance (Application No. 18/459,927) for a “Curcumin nanoparticle complex having modified particle surface and method for preparing same.” (Image: Binotec)
HYDROCUMIN and the USPTO Notice of Allowance (Application No. 18/459,927) for a “Curcumin nanoparticle complex having modified particle surface and method for preparing same.” (Image: Binotec)

One-fifth the dose, 11.6 times the peak blood level

Absorption was compared in a human study. In a randomized, double-blind trial of 20 healthy adult men at Jeonbuk National University Hospital, taking 400 mg of HYDROCUMIN produced a peak blood concentration (Cmax) of 445.15 ng/mL, compared with 38.30 ng/mL after 2,000 mg of standard curcumin — 11.6 times higher. Total blood exposure (AUC) was 4.4 times higher.

Adjusted to the same dose, this corresponds to about 60 times the peak concentration and about 23 times the total exposure. An absorption-rate indicator also improved 3.83-fold. The study was published in the journal Scientific Reports under the title “Enhanced bioavailability of a novel double-layered nano-liposomal curcumin (BNT-C060): a randomized, double-blind, clinical trial.”

Human absorption of 400 mg HYDROCUMIN versus 2,000 mg standard curcumin. At one-fifth the intake, peak blood level was 11.6 times and total exposure 4.4 times higher. (Data: Binotec)
Human absorption of 400 mg HYDROCUMIN versus 2,000 mg standard curcumin. At one-fifth the intake, peak blood level was 11.6 times and total exposure 4.4 times higher. (Data: Binotec)

These figures were obtained with a specific formulation, dose and study design, and further review is needed before applying them to other products or everyday intake.

US patents for both the platform and the ingredient

Binotec obtained a US patent (US 12,318,462) and a European patent (EP 3995126) for its Absosome technology in 2025. HYDROCUMIN was patented in Korea in 2023 (KR 10-2488134) and filed in the United States and Europe through an international application (PCT/KR2022/014386). With this allowance, the company is set to hold US patents on both its delivery platform and the curcumin ingredient built on it.

Once the US grant is complete, Binotec plans to export HYDROCUMIN as an ingredient and supply it to brand companies in the US market, using its intellectual property in both the platform and the ingredient to expand in the global market for health functional food ingredients.

About Binotec

Binotec is a bio-materials company that applies drug-delivery technology to cosmetic and food ingredients. Its platforms include the skin carrier Hydroethosome®, the oral carrier Absosome™ and the fermentation platform Absobiome. In July 2026 it completed a GMP plant in Gyeongsan, North Gyeongsang Province, with an investment of about KRW 25 billion.

Binotec’s GMP plant in Gyeongsan, North Gyeongsang Province, completed in July 2026 with an investment of about KRW 25 billion. (Photo: Binotec)
Binotec’s GMP plant in Gyeongsan, North Gyeongsang Province, completed in July 2026 with an investment of about KRW 25 billion. (Photo: Binotec)

For the patent and absorption data to translate into market results, commercial supply agreements, product applications and follow-up research will be needed. How far HYDROCUMIN’s global ingredient supply expands is the next thing to watch.

Note: This article is based on materials provided by Binotec. The study results describe an ingredient and do not indicate the prevention or treatment of any disease.

Source: Binotec Co., Ltd. · binotec.co.kr
Media contact: FOB Holdings, Media Division · aninyoul@fobholdings.co.kr

This article is also available in: 한국어 · English · Français · 日本語 · हिन्दी · 简体中文 · العربية · ไทย